FDAnews Drug Daily Bulletin

TAKEDA AND GALAXY BIOTECH SIGN LICENSE AGREEMENT FOR GALAXY'S INVESTIGATIONAL ANTIBODIES FOR THE TREATMENT OF CANCER

July 11, 2006
A A

Takeda Pharmaceutical Company Limited ("Takeda") and Galaxy Biotech, LLC ("Galaxy") announced that on July 1, both parties have entered into an agreement for the development and marketing of HuL2G7, a humanized anti-Hepatocyte Growth Factor (HGF) monoclonal antibody created by Galaxy.
PipelineReview